What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis

PURPOSE: The optimum systemic therapies for advanced/metastatic renal cell carcinoma (RCC) of favourable, intermediate and poor risk have not been established. We aimed to compare and rank the effects associated with systemic therapies in the first-line setting. METHODS: We searched PubMed, Cochrane...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Guanghui, Wu, Xiaoqiang, Wang, Zhiwei, Tian, Xiangyong, Zhang, Chan, Wu, Xuan, Zhang, Haotian, Jing, Gaopeng, Yan, Tianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454197/
https://www.ncbi.nlm.nih.gov/pubmed/32859659
http://dx.doi.org/10.1136/bmjopen-2019-034626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454197/
https://www.ncbi.nlm.nih.gov/pubmed/32859659
http://dx.doi.org/10.1136/bmjopen-2019-034626

Ejemplares similares